ClinicalTrials.gg
CompletedNCT03283878Updated Nov 17, 2026Results posted

Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

A Phase 4 interventional study of Cefazolin in Arthropathy of Knee and Antibiotic Prophylaxis, sponsored by Duke University. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Duke University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,770
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty (TKA): Multi-Center Trial is a study that will compare the effectiveness of various perioperative strategies for antibiotic delivery as prophylaxis for periprosthetic joint infections (PJI) and surgical site infection in elective primary TKA. The investigators hypothesize that a single dose of prophylactic antibiotic administered within 60 minutes before the incision is not an effective way to prevent PJI in elective primary total knee arthroplasty (TKA). The investigators also hypothesize that the prolonged delivery (24 hours) of antibiotic prophylaxis after surgery does not further reduce the incidence of PJI in elective primary TKA.

Duke University is the only site recruiting both primary total knee arthroplasty and unilateral knee arthroplasty.

Read the detailed description

Total joint arthroplasty (TJA), is one of the most successful operations in modern medicine; however, it remains an expensive procedure in an era of constrained health care resources. Arthritis affects 49.9 million Americans with 21.1 million experiencing arthritis-attributable activity limitations. As these numbers are expected to increase significantly by 2030, the demand for primary total knee arthroplasties (TKA) by 673% to 3.48 million procedures/year. Periprosthetic joint infection (PJI), with its disastrous implications, continues to challenge the orthopaedic community. Practicing orthopaedic surgeons continue to invest efforts to minimize surgical site infection (SSI). Kamath et al. evaluated characteristics and resource utilization associated with revision arthroplasty for PJI using the Nationwide Inpatient Sample. The authors found that PJI was the most common indication for revision total knee arthroplasty (TKA), and the third most common reason for revision total hip arthroplasty (THA). Prophylactic antibiotics aim to provide protection against bacteria most likely to gain access to the surgical site during the procedure and in the perioperative period. The two most common bacteria causing contamination and subsequent deep infection in TKA are Staphylococcus aureus and coagulase-negative staphylococci.

While antibiotic regimens for antimicrobial prophylaxis might carry different risks and side-effect profiles, e.g., hypersensitivity reactions (including anaphylaxis), acute kidney injury, and Clostridium difficile infection, there are a number of studies which validate the importance of the preoperative dose of antibiotics in decreasing periprosthetic joint infection (PJI) and surgical site infection (SSI) in total joint arthroplasty (TJA). However, there are conflicting recommendations/guidelines as to the optimal timing and the optimal duration perioperative antibiotics. The American Academy of Orthopaedic Surgeons (AAOS), the Centers for Disease Control (CDC), and SCIP guidelines recommend that prophylactic antibiotics be completely infused within one hour before the surgical incision. The US advisory statement recommends that antimicrobial prophylaxis be administered within one hour before incision and discontinued within 24 hours after the end of the operation, while European guidelines recommend a single dose within 30 minutes before incision.

Recently, the Center for Disease Control (CDC) published its updated guidelines for prevention of SSI prevention that included a recommendation regarding peri-operative antibiotic prophylaxis. Based on their evaluation of the available literature, the CDC recommended that a single dose of peri-operative antibiotics be utilized for patients undergoing clean-contaminated surgical interventions, advocating for no prophylaxis after the incision is closed in the operating room. This guideline encompasses several surgeries where implants are utilized, including arthroplasty, spine fusion, and fracture fixation. Furthermore, it was classified as a category IA-strong recommendation with high quality evidence. However, much of the literature cited for this recommendation is based on cardiothoracic, vascular, and general surgeries, where few or no implants are utilized. It is important to recognize that these surgical cohort may behave differently from the orthopaedic patient population in terms of infection risk and severity of infection outcomes.

This clinical research protocol seeks to address the lack of knowledge and Level I data around the optimal antimicrobial prophylaxis and to address the question if a single preoperative dose is enough compared to additional postoperative prophylaxis. Several smaller clinical studies have used pre- and post-intervention periods to assess the effect of antibiotic duration for surgical prophylaxis. Tang et al launched a surgical wound infection surveillance program to monitor all orthopaedic surgeries and changed the prophylactic antibiotic regimen from intravenous cefuroxime (one preoperative and 2 postoperative doses every 8 hours) to one single preoperative dose of intravenous cefazolin for all clean orthopaedic surgeries. The authors of this study found no significant difference in the superficial and deep wound infection rates in 1,367 primary arthroplasties performed with a single preoperative dose of cefazolin versus 3 doses of cefuroxime. The deep wound infection rate for THA was 1.1% (95% CI, 0%-3.3%) in the cefuroxime group and 1.1% (95% CI, 0%-2.2%) in the cefazolin group (p=1.0). The deep wound infection rate of TKA was 1.6% (95% CI, 0%-3.8%) in the cefuroxime group and 1.0% (95% CI, 0.3%-1.7%) in the cefazolin group (p=0.63).121 In a retrospective review of 1,341 TJAs, Williams and Gustilo found no difference in deep infection rates between a 3 day and 1 day course of prophylactic antibiotics, but emphasized the importance of the preoperative dose, which was 2g of cefazolin. Mauerhan compared the efficacy of a one-day regimen of cefuroxime with a 3-day regimen of cefazolin in a prospective, double-blinded, multicenter study of 1,354 patients treated with arthroplasty and concluded that there was no significant difference in the prevalence of wound infections between the two groups.[34] In the group treated with primary THA, the prevalence of deep wound infection was 0.5% (1/187) for those treated with cefuroxime compared with 1.2% (2/168) for those who had received cefazolin. In the group treated with a primary TKA, the rate of deep wound infection was 0.6% (1/178) for those treated with cefuroxime compared with 1.4% (3/207) for those who had received cefazolin. Heydemann and Nelson, in a study of hip and knee arthroplasty procedures, initially compared a 24-hour regimen of either nafcillin or cefazolin with a 7-day regimen of the same and found no difference in the prevalence of infection. They then compared a single preoperative dose with a 48-hour regimen and again found no difference in infection prevalence. A total of 466 procedures was performed during the 4-year study. No deep infections developed in either the one-dose or 48-hour antibiotic protocol group. A deep infection developed in one (0.8%) of the 127 patients in the 24-hour protocol group and in two (1.6%) of the 128 patients in the 7-day protocol group for an overall infection rate of 0.6% (3/466). The authors recognized that as a result of the small sample sizes, the study lacked the power to compare the one dose and the more than one dose categories. In two trials, a total of 1609 patients were randomly assigned to receive 1.5 g of cefuroxime intravenously every 8 hours for a total of 16 hours (n = 1511) or 24 hours (n = 98) postoperatively versus 1600 patients given no postoperative prophylaxis. Both studies showed no difference between treatment groups suggesting that current available evidence may not support the efficacy of postoperative antibiotic prophylaxis for the prevention of surgical-site infections.

Antibiotics have been a critical public health tool since the discovery of penicillin in 1928, saving the lives of millions of people around the world. Today, however, the emergence of drug resistance in bacteria is reversing the miracles of the past eighty years, with drug choices for the treatment of many bacterial infections becoming increasingly limited, expensive, and, in some cases, nonexistent. The Centers for Disease Control and Prevention (CDC) estimates that drug-resistant bacteria cause two million illnesses and approximately 23,000 deaths each year in the United States alone. The Centers for Disease Control and Prevention (CDC) estimates that drug-resistant bacteria cause two million illnesses and approximately 23,000 deaths each year in the United States alone (https://www.cdc.gov/drugresistance/). The National Action Plan for Combating Antibiotic-resistant Bacteria provides a roadmap to guide the Nation in rising to this challenge. Developed in response to Executive Order 13676: Combating Antibiotic-Resistant Bacteria - issued by President Barack Obama on September 18, 2014 - the National Action Plan outlines steps for implementing the National Strategy for Combating Antibiotic-Resistant Bacteria and addressing the policy recommendations with regard to antibiotic stewardship as outlined by the President's Council of Advisors on Science and Technology (PCAST). One of the goals of the National Action Plan is the implementation of evidence-based infection control practices can prevent the spread of resistant pathogens and questions the way surgeons use prophylactic antibiotics in the preoperative period.

The scientific rationale for antibiotic prophylaxis is to inhibit or eliminate contaminating microorganisms that gain access to the surgical site during the procedure. Thus, the goal of administering preoperative antibiotics is to allow for adequate tissue (blood, soft tissue, and bone) concentrations by the time of incision. Thus, these antibiotics should exceed the minimum inhibitory concentration (MIC) for the organisms most likely to be encountered for the duration of the operation. While the role of perioperative antibiotic prophylaxis is well established, controversy exists about best clinical practice guidelines with regard to antibiotic regimen and route of administration. The results of the proposed study will be used to establish a clinical practice guidelines for antimicrobial prophylaxis in elective total joint arthroplasty.

02

Conditions studied

  • Arthropathy of Knee
  • Antibiotic Prophylaxis
03

In context

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 272 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥ 18 years of age
  • Patient has no open wounds on operative leg
  • Patient is scheduled to undergo elective total knee arthroplasty for posttraumatic, osteoarthritis, avascular necrosis, and/or inflammatory arthritis
  • Patient does not have active infection on the operative leg, the operative joint
  • Patient is willing to cooperate and follow study protocol and visit schedule

Exclusion criteria

Exclusion Criteria:

  • Patient is ≤ 18 years of age
  • Patient is pregnant
  • Patient is unable to provide written consent
  • Patient has psychiatric disorder that precludes safe study participation or that necessitates confinement in a custodial environment at home or in a chronic care facility
  • Patient has traumatic injury that requires emergent or urgent total knee arthroplasty (e.g. fracture)
  • Patient has active infections in the operative leg/joint
  • Patient has severe dementia
  • Suspicion of illicit drug abuse by patient. Patients who use prescription cannabinoids are not excluded from enrollment.
  • of 5 \& 6
  • No application of topical antibiotic powder such as vancomycin or antibiotic beads in surgical wound
  • Intra-operative re-dosing other than specified re-dosing intervals or without excessive blood loss (\<1500mL)
  • History of prior native septic knee arthritis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,770 participants (actual)

Study arms

  • Experimental
    Study Group 1

    Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given. \< 120 kg - patients will receive 2 grams of cefazolin ≥ 120 kg - patient will receive 3 grams of cefazolin Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose.

    Drug: Cefazolin

  • Experimental
    Study Group 2

    Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively. \< 120 kg - patients will receive 2 grams of cefazolin ≥ 120 kg - patient will receive 3 grams of cefazolin Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.).

    Drug: Cefazolin

Interventions

  • Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1. Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2.

    Also known as: Ancef

06

What researchers measure

Primary outcomes

  1. Number of Participants With Periprosthetic Infection (PJI) as Measured by Chart Review

    Time frame: up to 90 days post-operative

Secondary outcomes

  1. Costs of Antibiotic Treatment Per Participant

    Determined by costs summed over all patients within each treatment group, divided by the corresponding group size.

    Time frame: up to 24 hours postoperative

Other outcomes

  1. Number of Participants With Periprosthetic Infection (PJI)

    Measured by phone call, email, letter and/or secured messaging via electronical medical record system

    Time frame: 90 days to 12 months post-operative

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneStudy Group 1Study Group 2
Started860860
Completed793818
Not completed6742
Withdrew: Physician decision3932
Withdrew: Withdrawal by subject2810

Outcome measures

PrimaryNumber of Participants With Periprosthetic Infection (PJI) as Measured by Chart Review
Time frame:
up to 90 days post-operative
Reported as:
Count of participants · Participants
Number of Participants With Periprosthetic Infection (PJI) as Measured by Chart Review
ParticipantsStudy Group 1Study Group 2
Number of Participants With Periprosthetic Infection (PJI) as Measured by Chart Review67
Statistical analysis
  • Study Group 1 vs Study Group 2 · Farrington-Manning · p = 0.0431 (Threshold for statistical significance is one-sided alpha=0.05.) · Risk difference (rd): -0.0010 · 90% CI -0.0092 to 0.0071Risk Difference = Study Group 1 (P1) minus Study Group 2 (P2)
SecondaryCosts of Antibiotic Treatment Per Participant

Determined by costs summed over all patients within each treatment group, divided by the corresponding group size.

Time frame:
up to 24 hours postoperative
Reported as:
Mean · US dollars
Costs of Antibiotic Treatment Per Participant
US dollarsStudy Group 1Study Group 2
Costs of Antibiotic Treatment Per Participant7.93 ± 0.3124.56 ± 6.43
Statistical analysis
  • Study Group 1 vs Study Group 2 · Mean difference (final values): 15.96 · 95% CI 15.53 to 16.38Mean cost savings (US dollars) per joint if single dose of antibiotics administered.
Other pre-specifiedNumber of Participants With Periprosthetic Infection (PJI)

Measured by phone call, email, letter and/or secured messaging via electronical medical record system

Time frame:
90 days to 12 months post-operative
Reported as:
Count of participants · Participants
Number of Participants With Periprosthetic Infection (PJI)
ParticipantsStudy Group 1Study Group 2
Number of Participants With Periprosthetic Infection (PJI)00
Statistical analysis
  • Study Group 1 vs Study Group 2 · Farrington-Manning · p = 0.0447 (Threshold for statistical significance is one-sided alpha=0.05.) · Risk difference (rd): 0.0000 · 90% CI -0.0073 to 0.0073Risk Difference = Study Group 1 (P1) minus Study Group 2 (P2)

Adverse events

Collected over Randomization to 90 (+14) days post-operative. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Group 11/793 (0.1%)10/793 (1.3%)16/793 (2%)
Study Group 22/818 (0.2%)12/818 (1.5%)17/818 (2.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventStudy Group 1Study Group 2
Periprosthetic Joint InfectionInfections and Infestations3/7931/818
Cerebrovascular AccidentNervous System Disorders0/7933/818
Surgical Site InfectionInfections and Infestations2/7930/818
Pulmonary EmbolismRespiratory, Thoracic and Mediastinal Disorders2/7931/818
Deep Vein ThrombosisVascular Disorders1/7932/818
AystoleCardiac Disorders1/7930/818
COVIDInfections and Infestations1/7930/818
Gastrointestinal BleedGastrointestinal Disorders1/7930/818
Delayed Wound HealingInjury, Poisoning and Procedural Complications1/7930/818
Bacterial InfectionInfections and Infestations0/7931/818
Most frequent other events
Showing 10 of 24
Most frequent other events
EventStudy Group 1Study Group 2
ArthrofibrosisMusculoskeletal and Connective Tissue Disorders1/7934/818
RashSkin and Subcutaneous Tissue Disorders2/7933/818
Urinary Tract InfectionInfections and Infestations2/7931/818
CellulitisInfections and Infestations0/7932/818
Deep Vein ThrombosisVascular Disorders1/7932/818
BradycardiaCardiac Disorders1/7930/818
Wound DehiscenceInjury, Poisoning and Procedural Complications1/7930/818
SyncopeNervous System Disorders1/7930/818
Coronary Artery DiseaseCardiac Disorders1/7930/818
Felxion ContractureMusculoskeletal and Connective Tissue Disorders1/7930/818

Baseline characteristics

Participants who had surgery as scheduled.

Age, Continuous
Age, Continuous(years)Study Group 1Study Group 2Total
Mean67.0 ± 8.466.8 ± 8.666.9 ± 8.5
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Study Group 1Study Group 2Total
Sex/Gender — Female475482957
Sex/Gender — Male316333649
Sex/Gender — Unknown or Refused to Answer235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Study Group 1Study Group 2Total
Hispanic or Latino303464
Not Hispanic or Latino7177291446
Unknown or Not Reported4655101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study Group 1Study Group 2Total
American Indian or Alaska Native123
Asian201434
Native Hawaiian or Other Pacific Islander123
Black or African American161138299
White5726161188
More than one race224
Unknown or Not Reported364480
Region of Enrollment
Region of Enrollment(Participants)Study Group 1Study Group 2Total
United States7938181611
08

Study locations

14 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Maryland St. Joseph Medical Center & Orthopedic Associates
    Towson, Maryland 21204, United States
  • University Of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Mississippi Bone and Joint Clinic
    Starkville, Mississippi 39759, United States
  • University Orthopaedic Associates, LLC
    Somerset, New Jersey 08873, United States
  • NYU School of Medicine
    New York, New York 10003, United States
  • Duke University Medical Center
    Durham, North Carolina 27703, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
  • University of South Carolina
    Columbia, South Carolina 29208, United States
  • BaylorScott&White Research Institute
    Temple, Texas 76508, United States
  • Augusta Health
    Fishersville, Virginia 22939, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2024, 84 months.

Results were first posted in Nov 2026, 1 year 11 months after primary completion. A results delay was requested in Jul 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2017
First posted
Sep 14, 2017
StartActual
Oct 24, 2017
Primary completionActual
Nov 20, 2024
CompletionActual
Aug 22, 2025
Results delay requested
Jul 18, 2025
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRateNumber of periprosthetic infectionParticipants With Periprosthetic Infection (PJI) as measuredMeasured by chart reviewChart ReviewTime frame: 90 day post-op → up to 90 days post-operative
Nov 17, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • ChangedBefore Costs of antibiotic treatment as measured by costs summed over all patients and divided by group sizeNow Costs of Antibiotic Treatment Per ParticipantTime frame: up to 1 year → up to 24 hours postoperative
  • Changedother outcomeBefore Rate of periprosthetic infection (PJI) as measured by phone call, email, letter and/or secured messaging via electronical medical record systemNow Number of Participants With Periprosthetic Infection (PJI)Time frame: 12 months post-op → 90 days to 12 months post-operative
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRateNumber of periprosthetic infectionParticipants With Periprosthetic Infection (PJI) as measuredMeasured by chart reviewChart ReviewTime frame: 90 day post-op → up to 90 days post-operative
    Secondary outcomes 2 edited
    What changed in the outcomes
    • ChangedBefore Costs of antibiotic treatment as measured by costs summed over all patients and divided by group sizeNow Costs of Antibiotic Treatment Per ParticipantTime frame: up to 1 year → up to 24 hours postoperative
    • Changedother outcomeBefore Rate of periprosthetic infection (PJI) as measured by phone call, email, letter and/or secured messaging via electronical medical record systemNow Number of Participants With Periprosthetic Infection (PJI)Time frame: 12 months post-op → 90 days to 12 months post-operative
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03283878
Lead sponsor
Duke University
Collaborators
American Association of Hip and Knee Surgeons, Orthopedic Research and Education Foundation
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Oct 24, 2017
Primary completion
Nov 20, 2024
Completion
Aug 22, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Thorsten Seyler, MD
principal investigator · Duke University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefazolin

Start the discussion